Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
Abstract: An improved process for preparing N6 -substituted aminopurine ribofuranose nucleosides. Compounds of this type are known to be usefull in the prepartation of compounds having activitity at adenosine receptors, e.g. Adenosine A1 receptor. The process comprises the step of reacting a 6-halopurine ribofuranose nucleoside with an amine in the presence of CaCO3 , wherein acid is added to the reaction mixture.
Type:
Grant
Filed:
March 19, 2002
Date of Patent:
November 20, 2007
Assignee:
Glaxo Group Limited
Inventors:
Malcolm Berry, John C. Roberts, Shiping Xie
Abstract: The present invention is directed to the process for the preparation of 2?-deoxy-2?-halo-?-L-arabinofuranosyl nucleosides, and in particular, 2?-deoxy-2?-fluoro-?-L-arabinofuranosyl thymine (L-FMAU), from L-arabinose, which is commercially available and less expensive than L-ribose or L-xylose, in ten steps. All of the reagents and starting materials are inexpensive and no special equipment is required to carry out the reactions.
Abstract: The invention provides methods for synthesizing oligonucleotides using nucleoside monomers having carbonate protected hydroxyl groups that are deprotected with ?-effect nucleophiles. The ?-effect nucleophile irreversibly cleave the carbonate protecting groups while simultaneously oxidizing the internucleotide phosphite triester linkage to a phosphodiester linkage. The procedure may be carried out in aqueous solution at neutral to mildly basic pH. The method eliminates the need for separate deprotection and oxidation steps, and, since the use of acid to remove protecting groups is unnecessary, acid-induced depurination is avoided. Fluorescent or other readily detectable carbonate protecting groups can be used, enabling monitoring of individual reaction steps during oligonucleotide synthesis. The invention is particularly useful in the highly parallel, microscale synthesis of oligonucleotides.
Type:
Grant
Filed:
June 15, 2006
Date of Patent:
September 18, 2007
Assignee:
Agilent Technologies, Inc.
Inventors:
Douglas J. Dollinger, Marvin H. Caruthers, Jason R. Betley
Abstract: Surfaces containing high purity silica (silicon dioxide) exhibit high loading potential for nucleic acids. Formulations containing nucleic acids and materials which mask the electrostatic interactions between the nucleic acids and surfaces are disclosed. By masking the phosphate charges of the nucleic acids, undesired interactions may be minimized or eliminated, thereby allowing the covalent bonding of the nucleic acids to the surface to proceed. The use of such formulations additionally minimizes nonspecific binding of the nucleic acids to the surface. Examples of materials to be included in such formulations include cations, xanthines, hexoses, purines, arginine, lysine, polyarginine, polylysine, and quaternary ammonium salts.
Abstract: The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs. In particular, the invention provides 5-aldehydo-uracil nucleosides and derivatives thereof, and methods of administration thereof to increase the virus mutation rate in a virally infected cell.
Type:
Grant
Filed:
August 21, 2002
Date of Patent:
July 17, 2007
Assignee:
Koronis Pharmaceuticals, Incorporated
Inventors:
Ling Li, Alexander Gall, Richard Daifuku
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, T, Y, W, W1 and W2 are as defined herein.
Type:
Grant
Filed:
October 21, 2004
Date of Patent:
July 17, 2007
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Jesse D. Keicher, Natalia B. Dyatkina
Abstract: The present invention relates to a method of inhibiting cellular and protein attachment to substrates by applying a composition containing an effective amount of adherent N,O-carboxymethylchitosan to a substrate with such that cellular and protein attachment are prevented or greatly reduced.
Abstract: The present invention provides a highly stereoselective, simple and economical glycosylation process for preparation of ?-anomer enriched 21-deoxy-21,21-D-ribofuranosyl difluoronucleosides of formula (II), and physiologically acceptable slats thereof, in particular, the ?-enriched anomer of gemcitabine hydrochloride of formula (IIb) in purity of >99% is provided through utilization of a novel trichloroacetimidate of formula (I).
Type:
Grant
Filed:
January 13, 2006
Date of Patent:
June 26, 2007
Assignee:
Dabur Pharma Limited
Inventors:
Golak Chandra Maikap, Deependra Bhatt, Bijan Kumar Panda
Abstract: Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, phosphorodithioate, or other covalent linkages. The oligomers have substantially reduced exocyclic adducts deriving from acrylonitrile or related contaminants.
Type:
Grant
Filed:
December 28, 2004
Date of Patent:
June 5, 2007
Assignee:
Isis Pharmaceuticals, Inc.
Inventors:
Vasulinga T. Ravikumar, Muthiah Manoharan, Daniel C. Capaldi, Achim Krotz, Douglas L. Cole, Andrei Guzaev
Abstract: Methods for the formation of sulfurized oligonucleotides are provided. The methods allow for the formation of phosphorothioate linkages in the oligonucleotides or derivatives, without the need for complex solvent mixtures and repeated washing or solvent changes. Oligonucleotides having from about 8, and up to about 50, nucleotides can be sulfurized according to the methods of the invention with higher yields than have been previously reported.
Type:
Grant
Filed:
January 10, 2001
Date of Patent:
June 5, 2007
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
Douglas L. Cole, Vasulinga T. Ravikumar, Zacharia S. Cheruvallath
Abstract: A process for the synthesis of phosphorothioate oligonucleotides is provided which comprises assembling an oligonucleotide bound to a solid support in the presence of acetonitrile; prior to cleaving the oligonucleotide from the solid support removing the acetonitrile; and cleaving the oligonucleotide from the solid support. The process is particularly suited to the large scale synthesis of nucleotides. The acetonitrile may be removed from the solid support by one or both of drying and by washing with solvents. Preferred washing solvents comprise trialkylamines.
Type:
Grant
Filed:
June 5, 2003
Date of Patent:
June 5, 2007
Assignee:
Avecia Limited
Inventors:
Ben James Mellor, Donald Alfred Wellings, Mark Edward Douglas
Abstract: Provided are methods of producing phosphitylated compounds, including 3?-O-phosphoramidites, comprising the step of reacting a hydroxyl-containing compound with a phosphitylating agent in the presence of a phosphitylation activator selected from the group consisting of: (1) acid-base complexes derived from an amine base of Formula II wherein R3, R4, R5, R6, and R7 are independently hydrogen, C1–C10 alkyl, C3–C10 cycloalkyl, C6–C10 aryl, C7–C10 aralkyl, C1–C10 heteroalkyl, or C1–C10 heteroaryl, and at least one of R3, R4, R5, R6, and R7 is not hydrogen; (2) zwitterionic amine complexes; and (3) combinations of two or more thereof, to produce a phosphitylated compound. Further provided are methods for purifying phosphitylated compounds comprising the steps of providing a phosphitylated compound in a solution solvent, contacting said phosphitylated compound with a precipitation solvent, and precipitating said phosphitylated compound.
Type:
Grant
Filed:
November 16, 2004
Date of Patent:
May 15, 2007
Assignee:
Honeywell International Inc.
Inventors:
Christian Werner, Frank Nerenz, Andreas Kanschik-Conradsen, Kalakota S. Reddy
Abstract: Novel non-steroidal tricyclic quinolinone and tricyclic quinoline compounds and compositions that are agonists, partial agonists and/or antagonists for androgen receptors (AR), their preparation and their uses are described.
Type:
Grant
Filed:
February 22, 2002
Date of Patent:
May 8, 2007
Assignee:
Ligand Pharmaceuticals Incorporated
Inventors:
Robert I. Higuchi, Lin Zhi, Donald S. Karanewsky, Anthony W. Thompson, Thomas R. Caferro, Neelakandha S. Mani, Jyun-Hung Chen, Marquis L. Cummings, James P. Edwards, Mark E. Adams, Charlotte L. F. Deckhut
Abstract: The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes related diseases such as an insulin-resistant diseases and obesity.
Abstract: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, each of R, Y, W, W1 and W2 are as defined herein.
Type:
Grant
Filed:
June 4, 2004
Date of Patent:
April 10, 2007
Assignee:
Genelabs Technologies, Inc.
Inventors:
Christopher D. Roberts, Jesse D. Keicher
Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
Type:
Grant
Filed:
July 31, 2006
Date of Patent:
April 10, 2007
Assignees:
Merck & Co., Inc., ISIS Pharmaceuticals, Inc.
Inventors:
Anne B. Eldrup, Marija Prhavc, Phillip Dan Cook, Steven S. Carroll, David B. Olsen
Abstract: Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, phosphorodithioate, or other covalent linkages. The oligomers have substantially reduced exocyclic adducts deriving from acrylonitrile or related contaminants.
Type:
Grant
Filed:
September 14, 2004
Date of Patent:
April 3, 2007
Assignee:
Isis Pharmaceuticals, Inc.
Inventors:
Vasulinga T. Ravikumar, Muthiah Manoharan, Daniel C. Capaldi, Achim Krotz, Douglas L. Cole, Andrei Guzaev
Abstract: The present invention relates to improved methods for filling the skin for cosmetic or medical purposes. Compositions comprising carboxymethyl cellulose (CMC), polyethylene oxide (PEO) and calcium ions can be made and have physical properties that depend on the amounts and types of CMC, PEO, and calcium ions to form ioniclaly cross-linked gels. Compositions can be formed into microspheres, coascervates, gels, or membranes. Gels, microspheres and coascervates can be injected directly into a site for dermal filling. Membranes can be surgically introduced, where they swell to form hydrated gels. After introduction, the dermal filler persists for a period of time and then can disintegrate and be removed from the body.
Type:
Grant
Filed:
July 26, 2005
Date of Patent:
March 20, 2007
Assignee:
Fziomed, Inc.
Inventors:
Richard Berg, Samuel Falcone, William G. Oppelt, Stephanie M. Cortese
Abstract: Antimicrobial compounds having the formula as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.
Type:
Grant
Filed:
January 6, 2004
Date of Patent:
April 24, 2007
Assignee:
Abbott Laboratories
Inventors:
Yat Sun Or, Zhenkun Ma, Richard F. Clark, Daniel T. Chu, Jacob J. Plattner, George Griesgraber